Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors

Human Gene Therapy

Volumn 10, Issue 11, 1999, Pages 1773-1781

  Pastore, Lucio ^a   Morral, Nuria ^a,b   Zhou, Heshan ^a   Garcia, Racel ^a   Parks, Robin J ^c   Kochanek, Stefan ^a,d   Graham, Frank L ^c   Lee, Brendan ^a   Beaudet, Arthur L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; HELPER VIRUS; IMMUNE RESPONSE; LIVER; LIVER FUNCTION; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TRANSGENE;

ADENOVIRIDAE; ALPHA 1-ANTITRYPSIN; ANIMALS; ANTIBODIES; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HELPER VIRUSES; HUMANS; LIVER; MICE; MICE, INBRED C3H; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); TRANSGENES;

ADENOVIRIDAE; ANIMALIA;

EID: 0033587482     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017455     Document Type: Article

References (46)

1. AMALFITANO, A., HAUSER, M.A., HU, H., SERRA, D., BEGY, C.R., and CHAMBERLAIN, J.S. (1998). Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 72, 926-933.
2. BARR, D., TUBB, J., FERGUSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M.A. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
3. BETT, A.J., HADDARA, W., PREVEC, L., and GRAHAM, F.L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U.S.A. 91, 8802-8806.
4. BOUCHER, R.C., KNOWLES, M.R., JOHNSON, L.G., OLSEN, J.C., PICKLES, R., WILSON, J.M., ENGELHARDT, J., YANG, Y., and GROSSMAN, M. (1994). Gene therapy for cystic fibrosis using E1-deleted adenovirus: A phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. Hum. Gene Ther. 5, 615-639.
5. BULLARD, D.C., KUNKEL, E.J., KUBO, H., HICKS, M.J., LORENZO, I., DOYLE, N.A., DOERSCHUK, C.M., LEY, K., and BEAUDET, A.L. (1996). Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice. J. Exp. Med. 183, 2329-2336.
6. CONNELLY, S., GARDNER, J.M., McCLELLAND, A., and KALEKO, M. (1996). High-level tissue-specific expression of functional human factor VIII in mice. Hum. Gene Ther. 7, 183-195.
7. ENGELHARDT, J.F., SIMON, R.H., YANG, Y., ZEPEDA, M., WEBER-PENDLETON, S., DORANZ, B., GROSSMAN, M., and WILSON, J.M. (1993). Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: Biological efficacy study. Hum. Gene Ther. 4, 759-769.
8. ENGELHARDT, J.F., LITZKY, L., and WILSON, J.M. (1994a). Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5, 1217-1229.
9. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994b). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91, 6196-6200.
10. - recombinant adenoviral vectors containing a temperature-sensitive E2a mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 3, 217-222.
11. FISHER, K.J., CHOI, H., BURDA, J., CHEN, S.J., and WILSON, J.M. (1996). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22.
12. GAO, G.-P., YANG, Y., and WILSON, J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934-8943.
13. HITT, M., ADDISON, C., and GRAHAM, F.L. (1997). Human adenovirus vectors for gene transfer into mammalian cells. Adv. Pharmacol. 40, 137-206.
14. HITT, M., PARKS, R.J., and GRAHAM, F.L. (1998). Structure and genetics organization of adenovirus vectors. In The Development of Gene Therapy. T. Friedman, ed. (Cold Spring Harbor Press, Cold Spring Harbor, NY) pp. 61-86.
15. HUARD, J., LOCHMULLER, H., ACSADI, G., JANI, A., MASSIE, B., and KARPATI, G. (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2, 107-115.
16. ISHIBASHI, S., BROWN, M.S., GOLDSTEIN, J.L., GERARD, R.D., HAMMER, R.E., and HERZ, J. (1993). Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 882-893.
17. JOOSS, K., YANG, Y., FISHER, K.J., and WILSON, J.M. (1998). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72, 4212-4223.
18. 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 89, 89-93.
19. ash mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter. Hum. Gene Ther. 7, 821-830.
20. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93, 5731-5736.
21. LE GAL LA SALLE, G., ROBERT, J.J., BERRARD, S., RIDOUX, V., STRATFORD-PERRICAUDET, L., PERRICAUDET, M., and MALLET, J. (1993). An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259, 988-990.
22. LIEBER, A., HE, C.-Y., KIRILLOVA, I., and KAY, M.A. (1996). Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70, 8944-8960.
23. MITANI, K., GRAHAM, F.L., CASKEY, C.T., and KOCHANEK, S. (1995). Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl. Acad. Sci. U.S.A. 92, 3854-3858.
24. MORRAL, N., O'NEAL, W., ZHOU, H., LANGSTON, C., and BEAUDET, A. (1997). Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther. 8, 1275-1286.
25. MORRAL, N., PARKS, R.J., ZHOU, H., LANGSTON, C., SCHIEDNER, G., QUINONES, J., GRAHAM, F.L., KOCHANEK, S., and BEAUDET, A.L. (1998). High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alphal-antitrypsin with negligible toxicity. Hum. Gene Ther. 9, 2709-2716.
26. MORSY, M.A., GU, M.C., MOTZEL, S., ZHAO, J., LIN, J., SU, Q., ALLAN, H., FRANLIN, L., PARKS, R.J., GRAHAM, F.L., KOCHANEK, S., BETT, A.J., and CASKEY, C.T. (1998). An adenoviral vector deleted for all coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95, 7866-7871.
27. O'NEAL, W.K., ZHOU, H., MORRAL, N., AGUILAR-CORDOVA, E., PESTANER, J., LANGSTON, C., MULL, B., WANG, Y., BEAUDET, A.L., and LEE, B. (1998). Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. Hum. Gene Ther. 9, 1587-1598.
28. PARKS, R.J., CHEN, L., ANTON, M., SANKAR, U., RUDNICKI, M.A., and GRAHAM, F.L. (1996). A new helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570.
29. PINKERT, C.A., ORNITZ, D.M., BRINSTER, R.L., and PALMITTER, R.D. (1987). An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev. 1, 268-276.
30. 1-antitrypsin gene to the lung epithelium in vivo. Science 252, 431-434.
31. SAMBROOK, J., FRITSCH, E.F., and MANIATIS, T. (1989). Molecular Cloning: A Laboratory Manual. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
32. SCHIEDNER, G., MORRAL, N., PARKS, R.J., WU, Y., KOOPMANS, S.C., LANGSTON, C., GRAHAM, F.L., BEAUDET, A.L., and KOCHANEK, S. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. 18, 180-183.
33. SMITH, T.A., MEHAFFEY, M.G., KAYDA, D.B., SAUNDERS, J.M., YEI, S., TRAPNELL, B.C., McCLELLAND, A., and KALEKO, M. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet. 5, 397-402.
34. STEWART, A.K., LASSAM, N., GRAHAM, F.L., GAULDIE, J., ADDISON, C.L., BAILEY, D.J., DESSUREAULT, S., DUBE, I.D., GALLENGER, S., KRAJDEN, M., ROTSTEIN, L.E., QUIRT, I.C., and MOEN, R. (1997). Clinical protocol: A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. Hum. Gene Ther. 8, 1403-1414.
35. STEWART, A.K., LASSAM, N., QUIRT, I.C., BAILEY, D.J., ROTSTEIN, L.E., KRAJDEN, M., DESSUREAULT, S., GALLINGER, S., CAPPE, D., WAN, Y.H., ADDISON, C.L., MOEN, R.C., GAULDIE, J., and GRAHAM, F.L. (1999). Adenovector mediated gene delivery of interleukin 2 in metastatic breast cancer and melanoma: Results of a phase I clinical trial. Gene Ther. 6, 350-363.
36. STRATFORD-PERRICAUDET, L.D., LEVRERO, M., CHASSE, J.-F., PERRICAUDET, M., and BRIAND, P. (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum. Gene Ther. 1, 241-256.
37. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545-550.
38. WORGALL, S., WOLFF, G., FALCK-PEDERSEN, E., and CRYSTAL, R.G. (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37-44.
39. + CTLs in vivo. J Immunol. 155, 2564-2570.
40. YANG, Y., ERTL, H.C., and WILSON, J.M. (1994a). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1, 433-442.
41. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1994b). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
42. YANG, Y., NUNES, F.A., BERENCSI, K., GONCZOL, E., ENGELHARDT, J.F., and WILSON, J.M. (1994c). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. 7, 362-369.
43. YANG, Y., LI, Q., ERTL, H.C., and WILSON, J.M. (1995a). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
44. YANG, Y., XIANG, Z., ERTL, H.C., and WILSON, J.M. (1995b). Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 92, 7257-7261.
45. YANG, Y., SU, Q., and WILSON, J.M. (1996). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 70, 7209-7212.
46. ZHOU, H., O'NEAL, W., MORRAL, N., and BEAUDET, A.L. (1996). Development of a complementing cell line and a system for construction of adenoviral vectors deleted for E1 and E2a. J. Virol. 70, 7030-7038.